Glenmark Pharmaceuticals Ltd

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of branded generics, generics, and specialty products. With a strong R&D pipeline, it aims to discover new chemical and biological entities, maintaining a significant presence across India, North America, Europe, and emerging markets.

Key Financial Ratios of Glenmark Pharmaceuticals Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Glenmark Pharmaceuticals Ltd's P/E ratio (TTM) is -346.97, compared to the industry median of 30.91 and large cap median of 44.19.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Glenmark Pharmaceuticals Ltd's P/B ratio is 6.64, compared to the industry median of 3.69 and large cap median of 6.64.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Glenmark Pharmaceuticals Ltd's P/S ratio is 4.10, compared to the industry median of 3.74 and large cap median of 6.84.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Glenmark Pharmaceuticals Ltd's PEG ratio is 0.65.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Glenmark Pharmaceuticals Ltd's EV/EBITDA ratio is 24.98.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Glenmark Pharmaceuticals Ltd's ROE is 12.96%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Glenmark Pharmaceuticals Ltd's ROA is 22.97%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Glenmark Pharmaceuticals Ltd's ROCE is 40%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Glenmark Pharmaceuticals Ltd's operating margin is 26.92%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Glenmark Pharmaceuticals Ltd's net margin is 8.02%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Glenmark Pharmaceuticals Ltd's current ratio is 1.48.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Glenmark Pharmaceuticals Ltd's debt-to-equity ratio is 0.05.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Glenmark Pharmaceuticals Ltd's interest coverage ratio is 10.50.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Glenmark Pharmaceuticals Ltd's DPS is ₹2.41.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Glenmark Pharmaceuticals Ltd's EPS is 30.05.

(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹2470.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1977

• Headquarters: Mumbai, Maharashtra

• Core Offerings: Branded Generics, Generics, Specialty Products, Active Pharmaceutical Ingredients (APIs), Novel Drug Discovery (NBE/NCE)

• Stock Listing: NSE (GLENMARK), BSE (532296)

• Promoter: Saldanha Family / Glenn Saldanha

History of Glenmark Pharmaceuticals Ltd

Founded in 1977 by Gracias Saldanha, Glenmark Pharmaceuticals began as a generics and branded generics company. The company expanded its global footprint, particularly focusing on therapeutic areas like dermatology, respiratory, and oncology. A significant milestone in the early 2000s was its foray into novel drug discovery, which led to substantial R&D investments and several drug candidates. Glenmark has continuously enhanced its manufacturing capabilities and market presence across India, the US, and emerging markets.

Business Segments and Revenue Mix

• India Formulations: Focuses on branded generics across therapeutic areas like dermatology, respiratory, cardiac, diabetes, and oncology, leveraging a strong sales and marketing network.

• North America Formulations: Primarily comprises generic products, with a growing presence in specialty generics, catering to the US market.

• Europe Formulations: Operates in key European markets, offering both branded and generic products, with an emphasis on respiratory and dermatology.

• Rest of World (RoW): Covers emerging markets across Latin America, Africa, Asia (excluding India), and CIS, driven by branded generic sales and strategic partnerships.

• Active Pharmaceutical Ingredients (API) Business: Supplies high-quality APIs internally for captive consumption and externally to various pharmaceutical companies globally.

Key Personnel

Glenn Saldanha - Chairman & Managing Director: Son of the founder, he has been instrumental in transforming Glenmark into a research-driven, global pharmaceutical company with a focus on novel drug discovery and global expansion.

Subsidiaries and Associate Companies

• Glenmark Pharmaceuticals Inc., USA

• Glenmark Generics Limited (India)

• Glenmark Pharma AG (Switzerland)

• Glenmark Farmaceutica Ltda (Brazil)

Corporate Actions

In September 2023, Glenmark Pharma announced the sale of 75% stake in its API subsidiary, Glenmark Life Sciences Ltd., to Nirma Limited for ₹5,651.5 crore. No major recent bonus or rights issues on record.

References

1. Annual Report FY2024
2. Exchange Filings (NSE/BSE)
3. Financial Results Announcement Q4 FY2024